Estrogen + Progestin: No Clinical Benefit for Colorectal Cancer

Share this content:
(ChemotherapyAdvisor) – Results of extended follow-up to assess clinical relevance of the Women's Health Initiative (WHI) finding that use of estrogen plus progestin resulted in a lower rate of colorectal cancer do not support use of the combined hormone therapy, investigators concluded in the Journal of Clinical Oncology online September 24.

“No suggestion of reduced colorectal cancer mortality emerged with extended follow-up,” Michael S. Simon, MD, MPH, of the Karmanos Cancer Institute, Wayne State University, Detroit, MI, and colleagues noted.

The WHI trial randomly assigned postmenopausal women with an intact uterus to daily 0.625mg conjugated equine estrogen plus 2.5mg medroxyprogesterone acetate (n=8,506) or matching placebo (n=8,102). During the intervention phase of the trial, a 44% lower rate of diagnosis of colorectal cancer was observed in the estrogen plus progestin group.

“Consequently, review articles, position statements, and executive summaries of professional societies commonly listed reduction of colorectal cancer risk as a benefit of estrogen plus progestin use,” Dr. Simon noted.

After a mean of 5.6 years of intervention and 11.6 years of total follow-up, fewer cancers were diagnosed in the combined hormone therapy group, 0.12% per year vs the placebo group, 0.16% per year (HR 0.72; 95% CI, 0.56–0.94; P=0.014). In the estrogen plus progestin arm, the cancers detected more commonly had positive lymph nodes, 50.5%, vs 28.6% in the placebo arm (P<0.001) and were detected at a higher stage (regional or distant, 68.8% vs 51.4%; P=0.003).

The higher number of deaths from colorectal cancer in the combined hormone therapy group (37, vs 27 in the placebo arm) was not statistically significant (HR 1.29; 95% CI, 0.78–2.11; P=0.320).

“These findings, in a cancer that can run a fatal course if there is a delay in diagnosis, do not support a clinically meaningful benefit for use of estrogen plus progestin in colorectal cancer. Future studies of estrogen plus progestin use and colorectal cancer should go beyond incidence analyses to address influence on tumor characteristics, stage, and colorectal cancer mortality,” they concluded.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs